Incident and Prevalent Herpes Simplex Virus Type 2 Infection Increases Risk of HIV Acquisition Among Women in Uganda and Zimbabwe
Overview
Authors
Affiliations
Background: An association has been demonstrated between herpes simplex type 2 (HSV-2) and HIV infection among men, but prospective studies in women have yielded mixed results.
Objective: To estimate the effects of prevalent and incident HSV-2 infection on subsequent HIV acquisition among women in two African countries.
Design: Prospective cohort study.
Methods: HSV-2 and HIV serostatus were evaluated at enrollment and quarterly for 15-24 months among 4531 sexually active, HIV-uninfected women aged 18-35 years from Uganda and Zimbabwe. The association between prior HSV-2 infection and HIV acquisition was estimated using a marginal structural discrete survival model, adjusted for covariates.
Results: HSV-2 seroprevalence at enrollment was 52% in Uganda and 53% in Zimbabwe; seroincidence during follow-up was 9.6 and 8.8/100 person-years in Uganda and Zimbabwe, respectively. In Uganda, the hazard ratio (HR) for HIV was 2.8 [95% confidence interval (CI), 1.5-5.3] among women with seroprevalent HSV-2 and 4.6 (95% CI, 1.6-13.1) among women with seroincident HSV-2, adjusted for confounding. In Zimbabwe, the HR for HIV was 4.4 (95% CI, 2.7-7.2) among women with seroprevalent HSV-2, and 8.6 (95% CI, 4.3-17.1) among women with seroincident HSV-2, adjusted for confounding. The population attributable risk percent for HIV due to prevalent and incident HSV-2 infection was 42% in Uganda and 65% in Zimbabwe.
Conclusions: HSV-2 plays an important role in the acquisition of HIV among women. Efforts to implement known HSV-2 control measures, as well as identify additional measures to control HSV-2, are urgently needed to curb the spread of HIV.
Pillay R, Naidoo P, Duma Z, Bhengu K, Mpaka-Mbatha M, Nembe-Mafa N Biology (Basel). 2025; 13(12.
PMID: 39765717 PMC: 11673149. DOI: 10.3390/biology13121050.
The impact of sex on HIV immunopathogenesis and therapeutic interventions.
Mihealsick E, Word A, Scully E J Clin Invest. 2024; 134(18).
PMID: 39286972 PMC: 11405047. DOI: 10.1172/JCI180075.
Owen E, Jama M, Nahal B, Clarke E, Obasi A BMJ Glob Health. 2024; 9(7).
PMID: 38964882 PMC: 11227757. DOI: 10.1136/bmjgh-2024-015167.
Aravantinou M, Plagianos M, Kokogho A, Adebajo S, Nowak R, Shoyemi E AIDS Res Hum Retroviruses. 2023; 39(9):485-494.
PMID: 36825536 PMC: 10510689. DOI: 10.1089/AID.2022.0070.
Govender Y, Morrison C, Chen P, Gao X, Yamamoto H, Chipato T Sex Transm Infect. 2022; 99(5):311-316.
PMID: 36104248 PMC: 10011014. DOI: 10.1136/sextrans-2022-055458.